Na-Rae Shin1, Hyung-Won Ryu2, Je-Won Ko1, Sung-Hyeuk Park1, Heung-Joo Yuk2, Ha-Jung Kim1, Jong-Choon Kim1, Seong-Hun Jeong3, In-Sik Shin4. 1. College of Veterinary Medicine (BK21 project team), Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju 500-757, Republic of Korea. 2. Natural Medicine Research Center, Korea Research Institute of Bioscience&Biotechnology, 30 Yeongudanji-ro, Ochang-eup, Cheongwon-gu, Chungju-si, Chungbuk 28116, Republic of Korea. 3. Namhae Garlic Research Institute, Namhae-gun, Kyungnam 668-812, Republic of Korea. Electronic address: poi1977@hanmail.net. 4. College of Veterinary Medicine (BK21 project team), Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju 500-757, Republic of Korea. Electronic address: dvmshin@jnu.ac.kr.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Artemisia argyi is a traditional herbal medicine in Korea and commonly called as mugwort. It is traditionally used as food source and tea to control abdominal pain, dysmenorrhea, uterine hemorrhage, and inflammation. AIM OF THE STUDY: We investigated the effects of A. argyi (TOTAL) and dehydromatricarin A (DA), its active component on ovalbumin (OVA)-induced allergic asthma. MATERIALS AND METHODS: The animals were sensitized on day 0 and 14 by intraperitoneal injection of OVA with aluminum hydroxide. On day 21, 22 and 23 after the initial sensitization, the animals received an airway challenge with OVA for 1h using an ultrasonic nebulizer. TOTAL (50 and 100mg/kg) or DA (10 and 20mg/kg) were administered to mice by oral gavage once daily from day 18-23. Airway hyperresponsiveness (AHR) was measured 24h after final OVA challenge. RESULT: TOTAL and DA treated animals reduced inflammatory cell counts, cytokines and AHR in asthmatic animals, which was accompanied with inflammatory cell accumulation and mucus hypersecretion. Furthermore, TOTAL and DA significantly declined Erk phosphorylation and the expression of MMP-9 in asthmatic animals. CONCLUSION: In conclusion, we indicate that Total and DA suppress allergic inflammatory responses caused by OVA challenge. It was considered that A. argyi has a potential for treating allergic asthma.
ETHNOPHARMACOLOGICAL RELEVANCE: Artemisia argyi is a traditional herbal medicine in Korea and commonly called as mugwort. It is traditionally used as food source and tea to control abdominal pain, dysmenorrhea, uterine hemorrhage, and inflammation. AIM OF THE STUDY: We investigated the effects of A. argyi (TOTAL) and dehydromatricarin A (DA), its active component on ovalbumin (OVA)-induced allergic asthma. MATERIALS AND METHODS: The animals were sensitized on day 0 and 14 by intraperitoneal injection of OVA with aluminum hydroxide. On day 21, 22 and 23 after the initial sensitization, the animals received an airway challenge with OVA for 1h using an ultrasonic nebulizer. TOTAL (50 and 100mg/kg) or DA (10 and 20mg/kg) were administered to mice by oral gavage once daily from day 18-23. Airway hyperresponsiveness (AHR) was measured 24h after final OVA challenge. RESULT: TOTAL and DA treated animals reduced inflammatory cell counts, cytokines and AHR in asthmatic animals, which was accompanied with inflammatory cell accumulation and mucus hypersecretion. Furthermore, TOTAL and DA significantly declined Erk phosphorylation and the expression of MMP-9 in asthmatic animals. CONCLUSION: In conclusion, we indicate that Total and DA suppress allergic inflammatory responses caused by OVA challenge. It was considered that A. argyi has a potential for treating allergic asthma.
Authors: Amy M Zimmermann-Klemd; Jakob K Reinhardt; Anna Morath; Wolfgang W Schamel; Peter Steinberger; Judith Leitner; Roman Huber; Matthias Hamburger; Carsten Gründemann Journal: Front Pharmacol Date: 2020-04-08 Impact factor: 5.810
Authors: Seong Min Kim; Soo Jung Lee; Venu Venkatarame Gowda Saralamma; Sang Eun Ha; Preethi Vetrivel; Kebede Taye Desta; Jin Young Choi; Won Sup Lee; Sung Chul Shin; Gon-Sup Kim Journal: Int J Mol Med Date: 2019-09-09 Impact factor: 4.101
Authors: Aliya S Mamatova; Izabela Korona-Glowniak; Krystyna Skalicka-Woźniak; Aleksandra Józefczyk; Krzysztof K Wojtanowski; Tomasz Baj; Zuriyadda B Sakipova; Anna Malm Journal: BMC Complement Altern Med Date: 2019-10-28 Impact factor: 3.659